CAMBRIDGE, UNITED KINGDOM, MONTREAL, CANADA--(Marketwire - January 07, 2008) - ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI), announced today that the incorporation of Pathogen Removal and Diagnostic Technologies Inc.'s ("PRDT") concentration technology to commercially available post mortem diagnostic tests for bovine spongiform encephalopathy ("BSE") could vastly improve the sensitivity of these tests by as much as 80-fold.
